Display options
Cite
Takagi K, Takayama T, Nagase H, et al. High TSC22D3 and low GBP1 expression in the liver is a risk factor for early recurrence of hepatocellular carcinoma. Exp Ther Med. 2011;2(3):425-431doi: 10.3892/etm.2011.236.
Takagi, K., Takayama, T., Nagase, H., Moriguchi, M., Wang, X., Hirayanagi, K., Suzuki, T., Hasegawa, H., Ochiai, T., Yamaguchi, N., Kochi, M., Kimura, M., & Esumi, M. (2011). High TSC22D3 and low GBP1 expression in the liver is a risk factor for early recurrence of hepatocellular carcinoma. Experimental and therapeutic medicine, 2(3), 425-431. https://doi.org/10.3892/etm.2011.236
Takagi, Keiko, et al. "High TSC22D3 and low GBP1 expression in the liver is a risk factor for early recurrence of hepatocellular carcinoma." Experimental and therapeutic medicine vol. 2,3 (2011): 425-431. doi: https://doi.org/10.3892/etm.2011.236
Takagi K, Takayama T, Nagase H, Moriguchi M, Wang X, Hirayanagi K, Suzuki T, Hasegawa H, Ochiai T, Yamaguchi N, Kochi M, Kimura M, Esumi M. High TSC22D3 and low GBP1 expression in the liver is a risk factor for early recurrence of hepatocellular carcinoma. Exp Ther Med. 2011 May;2(3):425-431. doi: 10.3892/etm.2011.236. Epub 2011 Mar 21. PMID: 22977521; PMCID: PMC3440698.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2011 May;2(3):425-431. doi: 10.3892/etm.2011.236. Epub 2011 Mar 21.

High TSC22D3 and low GBP1 expression in the liver is a risk factor for early recurrence of hepatocellular carcinoma.

Experimental and therapeutic medicine

Keiko Takagi, Tadatoshi Takayama, Hiroki Nagase, Masamichi Moriguchi, Xiaofei Wang, Kaname Hirayanagi, Tsukasa Suzuki, Hiromasa Hasegawa, Takanaga Ochiai, Nobuhisa Yamaguchi, Mitsugu Kochi, Makoto Kimura, Mariko Esumi

Affiliations

  1. Departments of Digestive Surgery.

PMID: 22977521 PMCID: PMC3440698 DOI: 10.3892/etm.2011.236

Abstract

Recurrence after liver resection for hepatocellular carcinoma (HCC) is a major clinical problem, and prognostic markers for recurrence are urgently required. For 390 HCC cases, segmented linear regression analysis with two segments was performed, and the interval for the early and late recurrence groups was partitioned at the crosspoint (676 days). We investigated whether gene expression in non-tumorous tissues of remnant liver from 39 hepatitis C virus-positive HCC cases may be associated with early recurrence of this disease. By microarray analysis, 21 genes were identified as candidate recurrence-associated genes. Further gene expression analysis was performed, and the localization and expression of the gene products of these candidate genes were immunohistochemically evaluated. Low expression of the GBP1 gene and high expression of the TSC22D3 gene were significantly (both P=0.04) associated with the risk of early recurrence. Through backward step-wise multivariate logistic regression analysis for the 21 candidate genes, high expression of GBP1 reduced [odds ratio (OR)=0.20; 95% confidence interval (CI) 0.06-0.73, P=0.02] and high expression of TSC22D3 increased the risk of early recurrence (OR=19.6; 95% CI 1.14-337.2; P=0.04). Immunohistochemical analysis revealed that hepatocytes showed strong membranous expression for GBP1 in the late recurrence group, but weak membranous expression for GBP1 in the early recurrence group. TSC22D3 was frequently expressed in lymphocytes and in a few hepatocytes in tissues of the early recurrence group. Our observations suggest that the combination of the high expression of the TSC22D3 gene and low expression of the GBP1 gene in the non-tumorous tissue of the remnant liver is significantly associated with early recurrence after surgical resection of HCC.

References

  1. J Surg Oncol. 2004 Jan;85(1):36-41 - PubMed
  2. J Hepatol. 2003 Feb;38(2):200-7 - PubMed
  3. World J Surg. 2003 Mar;27(3):294-8 - PubMed
  4. Surgery. 2007 Mar;141(3):330-9 - PubMed
  5. Gastroenterology. 2006 Dec;131(6):1758-67 - PubMed
  6. Hepatology. 2002 Apr;35(4):853-60 - PubMed
  7. Hepatol Res. 2007 Sep;37(9):676-91 - PubMed
  8. J Viral Hepat. 2006 Oct;13(10):690-700 - PubMed
  9. Cancer Res. 2001 Mar 1;61(5):2129-37 - PubMed
  10. Cancer Res. 2003 Feb 15;63(4):859-64 - PubMed
  11. Br J Surg. 2002 Jan;89(1):57-62 - PubMed
  12. EMBO J. 2003 Aug 1;22(15):3772-82 - PubMed
  13. Int J Cancer. 2008 Nov 1;123(9):2120-9 - PubMed
  14. Mol Cancer. 2009 Oct 08;8:83 - PubMed
  15. Gastroenterology. 2001 Mar;120(4):955-66 - PubMed
  16. Oncogene. 2003 May 15;22(19):3007-14 - PubMed
  17. EMBO J. 2001 Oct 15;20(20):5568-77 - PubMed
  18. Mol Cancer. 2010 Apr 09;9:74 - PubMed
  19. Eur J Surg Oncol. 2003 Apr;29(3):266-71 - PubMed
  20. Clin Cancer Res. 2006 Aug 1;12(15):4720-9 - PubMed
  21. N Engl J Med. 2008 Nov 6;359(19):1995-2004 - PubMed
  22. J Gastroenterol Hepatol. 2007 Aug;22(8):1178-82 - PubMed
  23. Hepatogastroenterology. 1998 Aug;45 Suppl 3:1267-74 - PubMed
  24. Hepatology. 1991 Nov;14(5):802-5 - PubMed
  25. Cancer. 2000 Aug 1;89(3):500-7 - PubMed

Publication Types